The company might finally become an oncology player.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.